A biomanufacturing facility in Everett that Pfizer decided to shut down before it opened is getting a new lease on life, with a new owner and a 21-year lease to an unnamed global biopharmaceutical company. Read More
Editor’s note: William Canestaro is managing director at Seattle venture capital firm WRF Capital and leads the biotechnology investment team. … Read More
Seagen fielded multiple offers before agreeing to a whopping $43 billion acquisition by pharma giant Pfizer. The Seattle-area company revealed… Read More
